コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 compared the safety and efficacy of placebo, terazosin (10 mg daily), finasteride (5 mg daily), and t
2 e, and alpha(1) receptor antagonists such as terazosin (1b) are used to treat both hypertension and b
3 ), ARC-239 (540 nM), prazosin (4900 nM), and terazosin (5000 nM) correlated best with affinities prev
4 brogate the apoptotic effect of doxazosin or terazosin against human prostate cancer or smooth muscle
5 that the apoptotic activity of doxazosin and terazosin against prostate cells is independent of their
6 pha1-adrenoceptor antagonists (doxazosin and terazosin) against prostate cancer cells is independent
7 h was significantly higher than that in both terazosin/alfuzosin/doxazosin users (1.10%, P < 0.0001)
8 classified as tamsulosin users (n = 45,380), terazosin/alfuzosin/doxazosin users (n = 22,690), or con
11 over sites following local administration of terazosin (alpha(1)-antagonist), yohimbine (alpha(2)-ant
12 order with propranolol (beta-AR antagonist), terazosin (alpha1-AR antagonist), or vehicle for an addi
13 ctively (P<0.001 for the comparisons of both terazosin and combination therapy with finasteride and w
14 ctively (P<0.001 for the comparisons of both terazosin and combination therapy with finasteride and w
15 finasteride was not, and the combination of terazosin and finasteride was no more effective than ter
17 symptom scores in the placebo, finasteride, terazosin, and combination-therapy groups at one year we
18 alpha1-adrenoceptor antagonists, doxazosin, terazosin, and tamsulosin, against prostate cancer cell
19 induction, we examined whether doxazosin and terazosin (both piperazinyl quinazolines) affect prostat
20 ibited not only by the alpha(1)AR antagonist Terazosin but also by the CXCR2-specific allosteric inve
21 ngs demonstrate the ability of doxazosin and terazosin (but not tamsulosin) to suppress prostate canc
23 ation for treatment of symptomatic LUTS/BPH: terazosin, doxazosin, tamsulosin, alfuzosin and silodosi
24 forcement and reduced pellet intake, whereas terazosin enhanced motivation for pellets and reversed p
26 pha1-adrenoceptor antagonists, doxazosin and terazosin, exhibit a potent apoptotic effect against pro
27 renoceptor antagonists such as doxazosin and terazosin have been previously shown to induce apoptosis
28 ted in vivo and found to be more potent than terazosin in both a rat model of prostate tone and a dog
29 rtially rescued with the alpha1AR antagonist terazosin, indicating that alpha1AR signaling participat
30 lpha1-adrenoceptor antagonists doxazosin and terazosin induced apoptosis in prostate epithelial and s
32 usion of selective antagonists of alpha(1)- (terazosin) or alpha(2)- (atipamezole) receptors or of ei
33 t of prostate cancer cells with doxazosin or terazosin results in a significant loss of cell viabilit
34 dicated that 6FNE markedly depressed whereas terazosin strongly enhanced the apparent functional acti
37 In men with benign prostatic hyperplasia, terazosin was effective therapy, whereas finasteride was
38 cently the a1 adrenergic receptor antagonist terazosin was shown to activate PGK1, a possible target
39 changes in fos expression following 6FNE and terazosin were significantly greater than those followin